

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.11.2012.
- 2 As per the audited Balance Sheet as at 31st March, 2011, the Company's Net Worth had been completely eroded. Therefore, as required under Section 15 (1) of the Sick Industrial Companies (Special Provisions) Act, 1985, the company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR) for measures to be determined with respect to the company. Accordingly, the company is registered with the BIFR.
- 3 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 5 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 6 Statement of Assets and Liabilities:

₹ in Lakhs

	Particulars	As at	
		30.09.2012	31.03.2012
		UNAUDITED	AUDITED
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
(a)	Share capital	5,028.07	5,028.07
(b)	Reserves and surplus	(24,484.59)	(23,951.58)
(c)	Money received against share warrants	115.66	115.66
	Sub-total-Shareholders' funds	(19,340.86)	(18,807.85)
2	Non-current liabilities		
(a)	Long-term borrowings	1,157.34	1,520.14
(b)	Deferred tax liabilities (Net)	1,258.69	1,258.69
	Sub-total - Non-current liabilities	2,416.03	2,778.83
3	Current liabilities		
(a)	Short-term borrowings	7,344.51	7,718.33
(b)	Trade payables	3,523.33	2,947.85
(c)	Other current liabilities	31,723.40	29,443.49
(d)	Short-term provisions	642.30	512.12
	Sub-total -Current liabilities	43,233.54	40,621.80
	TOTAL-EQUITY AND LIABILITIES	26,308.71	24,592.77
B	ASSETS		
1	Non-current assets		
(a)	Fixed assets	7,392.25	7,665.69
(b)	Non-current investments	2,351.46	2,351.46
(c)	Long-term loans and advances	456.18	395.09
	Sub-total - Non-current assets	10,199.89	10,412.24
2	Current assets		
(a)	Inventories	4,030.13	4,024.70
(b)	Trade receivables	8,302.23	7,418.94
(c)	Cash and cash equivalents	335.41	1,758.50
(d)	Short-term loans and advances	3,441.05	978.39
(e)	Other current assets- Miscellaneous expenditure	-	-
	Sub-total - Current assets	16,108.82	14,180.53
	TOTAL ASSETS	26,308.71	24,592.77

Place: Mumbai.
Date: 12.11.2012



For MARKSANS PHARMA LIMITED

MARK SALDANHA
Managing Director.